275 related articles for article (PubMed ID: 23582272)
41. Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P
Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864
[TBL] [Abstract][Full Text] [Related]
42. Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
Xu RX; Rocque WJ; Lambert MH; Vanderwall DE; Luther MA; Nolte RT
J Mol Biol; 2004 Mar; 337(2):355-65. PubMed ID: 15003452
[TBL] [Abstract][Full Text] [Related]
43. The roles of phosphodiesterase 2 in the central nervous and peripheral systems.
Zhang C; Yu Y; Ruan L; Wang C; Pan J; Klabnik J; Lueptow L; Zhang HT; O'Donnell JM; Xu Y
Curr Pharm Des; 2015; 21(3):274-90. PubMed ID: 25159070
[TBL] [Abstract][Full Text] [Related]
44. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.
Tralau-Stewart CJ; Williamson RA; Nials AT; Gascoigne M; Dawson J; Hart GJ; Angell AD; Solanke YE; Lucas FS; Wiseman J; Ward P; Ranshaw LE; Knowles RG
J Pharmacol Exp Ther; 2011 Apr; 337(1):145-54. PubMed ID: 21205923
[TBL] [Abstract][Full Text] [Related]
45. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center.
Freund YR; Akama T; Alley MR; Antunes J; Dong C; Jarnagin K; Kimura R; Nieman JA; Maples KR; Plattner JJ; Rock F; Sharma R; Singh R; Sanders V; Zhou Y
FEBS Lett; 2012 Sep; 586(19):3410-4. PubMed ID: 22841723
[TBL] [Abstract][Full Text] [Related]
46. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).
Cameron RT; Coleman RG; Day JP; Yalla KC; Houslay MD; Adams DR; Shoichet BK; Baillie GS
Biochem Pharmacol; 2013 May; 85(9):1297-305. PubMed ID: 23473803
[TBL] [Abstract][Full Text] [Related]
47. A new chemical tool for exploring the physiological function of the PDE2 isozyme.
Chambers RJ; Abrams K; Garceau NY; Kamath AV; Manley CM; Lilley SC; Otte DA; Scott DO; Sheils AL; Tess DA; Vellekoop AS; Zhang Y; Lam KT
Bioorg Med Chem Lett; 2006 Jan; 16(2):307-10. PubMed ID: 16275071
[TBL] [Abstract][Full Text] [Related]
48. C-C bond formation at C-2 of a quinoline ring: synthesis of 2-(1H-indol-3-yl)quinoline-3-carbonitrile derivatives as a new class of PDE4 inhibitors.
Kumar KS; Kiran Kumar S; Yogi Sreenivas B; Gorja DR; Kapavarapu R; Rambabu D; Rama Krishna G; Reddy CM; Basaveswara Rao MV; Parsa KV; Pal M
Bioorg Med Chem; 2012 Apr; 20(7):2199-207. PubMed ID: 22386978
[TBL] [Abstract][Full Text] [Related]
49. Diastereoselective synthesis and profiling of bicyclic imidazolidinone derivatives bearing a difluoromethylated catechol unit as potent phosphodiesterase 4 inhibitors.
Dorokhov VS; Golovanov IS; Tartakovsky VA; Sukhorukov AY; Ioffe SL
Org Biomol Chem; 2018 Oct; 16(38):6900-6908. PubMed ID: 30024008
[TBL] [Abstract][Full Text] [Related]
50. Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration.
Ochiai K; Takita S; Kojima A; Eiraku T; Iwase K; Kishi T; Ohinata A; Yageta Y; Yasue T; Adams DR; Kohno Y
Bioorg Med Chem Lett; 2013 Jan; 23(1):375-81. PubMed ID: 23200255
[TBL] [Abstract][Full Text] [Related]
51. Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis.
Felding J; Sørensen MD; Poulsen TD; Larsen J; Andersson C; Refer P; Engell K; Ladefoged LG; Thormann T; Vinggaard AM; Hegardt P; Søhoel A; Nielsen SF
J Med Chem; 2014 Jul; 57(14):5893-903. PubMed ID: 24984230
[TBL] [Abstract][Full Text] [Related]
52. Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.
Hamblin JN; Angell TD; Ballantine SP; Cook CM; Cooper AW; Dawson J; Delves CJ; Jones PS; Lindvall M; Lucas FS; Mitchell CJ; Neu MY; Ranshaw LE; Solanke YE; Somers DO; Wiseman JO
Bioorg Med Chem Lett; 2008 Jul; 18(14):4237-41. PubMed ID: 18539455
[TBL] [Abstract][Full Text] [Related]
53. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.
Zheng S; Kaur G; Wang H; Li M; Macnaughtan M; Yang X; Reid S; Prestegard J; Wang B; Ke H
J Med Chem; 2008 Dec; 51(24):7673-88. PubMed ID: 19049349
[TBL] [Abstract][Full Text] [Related]
55. Assessing the emetic potential of PDE4 inhibitors in rats.
Robichaud A; Savoie C; Stamatiou PB; Lachance N; Jolicoeur P; Rasori R; Chan CC
Br J Pharmacol; 2002 Jan; 135(1):113-8. PubMed ID: 11786486
[TBL] [Abstract][Full Text] [Related]
56. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
Jacobitz S; McLaughlin MM; Livi GP; Burman M; Torphy TJ
Mol Pharmacol; 1996 Oct; 50(4):891-9. PubMed ID: 8863835
[TBL] [Abstract][Full Text] [Related]
57. Discovery of 2-(3,4-dialkoxyphenyl)-2-(substituted pyridazin-3-yl)acetonitriles as phosphodiesterase 4 inhibitors with anti-neuroinflammation potential based on three-dimensional quantitative structure-activity relationship study.
Huang C; Zhong QP; Tang L; Wang HT; Xu JP; Zhou ZZ
Chem Biol Drug Des; 2019 Apr; 93(4):484-502. PubMed ID: 30588755
[TBL] [Abstract][Full Text] [Related]
58. Phosphodiesterase 2 inhibitor Hcyb1 reverses corticosterone-induced neurotoxicity and depression-like behavior.
Zhu MJ; Shi J; Chen Y; Huang G; Zhu XW; Zhang S; Huang XF; Song GQ; Zhang HT; Ke HM; O'Donnell JM; Wang LQ; Xu Y
Psychopharmacology (Berl); 2020 Nov; 237(11):3215-3224. PubMed ID: 32926224
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis, and evaluation of 2-aryl-7-(3',4'-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors.
Kim I; Song JH; Park CM; Jeong JW; Kim HR; Ha JR; No Z; Hyun YL; Cho YS; Sook Kang N; Jeon DJ
Bioorg Med Chem Lett; 2010 Feb; 20(3):922-6. PubMed ID: 20053559
[TBL] [Abstract][Full Text] [Related]
60. Selaginpulvilins A-D, new phosphodiesterase-4 inhibitors with an unprecedented skeleton from Selaginella pulvinata.
Liu X; Luo HB; Huang YY; Bao JM; Tang GH; Chen YY; Wang J; Yin S
Org Lett; 2014 Jan; 16(1):282-5. PubMed ID: 24328835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
